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Abstract
Objective Description of the clinical response of 12
consecutive cases of disease-active ankylosing spondylitis
(AS) treated with the herbal medicine Tripterygium wilfor-
dii Hook f (TwHf; lei gong teng, thunder god vine), which
has been reported in controlled studies to be effective in
rheumatoid arthritis (RA).
Methods The clinical status of 12 patients with active AS who
w e r es t a r t e do n6 0m g d a y
-1 of a commercial tablet preparation
of TwHf extract. were monitored at weeks 1, 3, and 6.
Results Compared to baseline, there was significant improve-
mentinmeanvaluesofphysicianassessment,Bathankylosing
spondylitisdiseaseactivity index (BASDAI),Bathankylosing
spondylitis functional index (BASFI), and Bath ankylosing
spondylitis global score (BAS-G) at weeks 3 and 6, with no
changes in liver enzymes or complete blood count (CBC).
Conclusion A placebo-controlled double-blind study for
Tripterygium is warranted. Until then, this particular report
should be considered as case reports and not an endorse-
ment of the use of Tripterygium in clinical practice.
Keywords Ankylosing spondylitis.Lei gong teng.
Tripterygium wilfordii Hook f
Introduction
One of the medicinal herbs widely used used in China for
the treatment of autoimmune and inflammatory diseases is
the vine Tripterygium wilfordii Hook f (TwHf), also known
by the descriptive names lei gong teng, thunder god vine,
and seven-step vine [1–3]. A rapid pubmed search for the
keywords “Tripterygium” plus “inflammatory” yields a
total of 120 publications, while a search for “Tripterygium”
and “lupus” yields 30 publications. More than 21 autoim-
mune and inflammatory diseases have been reported to
have been treated with extracts of Tripterygium. At least
five pharmaceutical companies in China are marketing
extracts of T. wilfordii in tablet forms and have been
approved by the China State Food and Drug Administration
for use in rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE), and ankylosing spondylitis (AS).
They are being used by many rheumatologists and
nephrologists who practice traditional medicine in China
[1–3]. For example, for the Jiangsu Province Hospital of
Traditional Chinese Medicine in Nanjing, the number of
tablets of T. wilfordii prescribed in 2008 was 620,000, the
average per month in 2009 has been about 50,000. At least
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DOI 10.1007/s10067-010-1497-0three controlled double-blind studies for RAwith promising
results have been reported, one carried out in China and the
others in North America [4–7]. Beneficial effects were
observed in RA as early as 4 weeks after initiation of
Tripterygium. In vitro and animal model studies suggest
that Tripterygium is anti-inflammatory and immunosup-
pressive, partly by suppressing the generation of proin-
flammatory cytokines (reviewed in Ref. [1]).
However, no pubmed abstract-available studies have
been reported on AS. Search for literature in a Chinese
language database showed that the earliest report of the use
of T. wilfordii in AS was in 1981 [8]. Since then, at least
four other Chinese language papers have been published,
comprising a total of 175 AS patients (reviewed in Ref.
[3]). The efficacy of T. wilfordii was broadly described as
being nearly 90% effective. However, none of these
Chinese language papers assessed patients with internation-
ally standardized evaluation instruments. AS is an inflam-
matory arthritis affecting mainly the axial skeleton. Like
RA, AS also respond to treatment by nonsteroidal anti-
inflammatory drugs (NSAID), sulfasalazine, and, more
dramatically, to tumor necrosis factor (TNF) blockers.
Unlike RA, there is no good evidence that it responds well
to methotrexate, leflunomide, or hydroxychloroquine [9,
10]. This paper describes 12 consecutive disease-active AS
patients who were started on Tripterygium and evaluated
with internationally approved evaluation instruments. This
paper is a case report and not a randomized placebo-
controlled study. In our analysis, we attempted to evaluate
the possible significance of response to Tripterygium by
comparing the Tripterygium results to those of 26 AS
patients on placebo in a controlled study for etanercept.
Materials and methods
Patients receiving Tripterygium were those attending the
Jiangsu Province Hospital of Traditional Chinese Medicine,
Jiangsu, Nanjing, China. The study and informed consent
followed the guidance of the Hospital Institutional Research
Board (approval ref. no. 2009NL-1501). The study was
designed to arbitrarily include all consecutive patients
within a period of 4 months who satisified the following
criteria: They satisfied the 1984 Modified New York
Criteria for AS [11]. Their pelvis X-ray showed a
sacroiliitis score of ≥4 when combining scores of both
right and left sides. Their scores for Bath ankylosing
spondylitis disease activity index (BASDAI) and for spinal
pain were ≥40 on a scale of 0 to 100. They had failed
NSAID. Of the 12 patients, eight had failed ≥ 1 month
NSAID, while 8/12 had also failed ≥3 months of at least
one disease-modifying antirheumatic drugs (DMARD). All
prospective patients were advised of the antifertility effect
of Tripterygium. Following the standard practice in this
institute, excluded from Tripterygium treatment, were those
patients with potential family planning, or being positive
for hepatitis antigens, or showed elevated liver enzymes in
blood tests. A general evaluation was also carried out to
exclude those with significant co-morbidities. None of the
AS patients in this case report had psoriasis or active uveitis
or had used corticosteroids within the past 1 month.
Patients who were on NSAID and DMARD were allowed
to continue their medications with no increase in dosages.
The Tripterygium used in these 12 patients was manufac-
tured by the Zhe Jiang De En De Pharmaceutical (Zhejiang,
China), the supplier for this institute. The lot number of the
tablets was 0802102. The dose of the Tripterygium was
20 mg 3 times daily. Evaluations were carried out at entry
of study as well as at weeks 1, 3, and 6. After finishing the
6 weeks of observation, patients were followed by their
own personal physicians and not by the investigators.
The placebo patients were derived from a randomized
double-blind controlled study of etanercept carried in the
Chinese PLA General Hospital, Beijing, China. Placebo
was administered subcutaneously twice a week. The
selection of patients according to their disease severity
was similar to those of the Tripterygium patients in that the
BASDAI score at baseline should be ≥40 (scale 0–100).
Details were similar to those of another placebo/etanercept
study carried out also in the Chinese PLA General Hospital
reported recently [12]. This study also followed the guide-
lines of the local and national Institutional Review Boards.
Evaluations included physician and patient self-
assessment (Bath ankylosing spondylitis global score,
BAS-G) over the past week, joint count for swelling,
BASDAI, Bath ankylosing spondylitis functional index
(BASFI), and ranges of motion included in the Bath
ankylosing spondylitis metrology index (BASMI) [13–16].
Endpoints of clinical response were expressed as ASAS20
a n dA S A S 4 0[ 17]. Blood tests included erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), com-
plete blood count (CBC), and liver tests. For assessment of
possible side effects, in addition to laboratory tests and
general review of systems, also was enquired patients’ own
assessment of possible side effects.
For statistical evaluations, the overall significance of
each parameter of clinical response was first tested by the
Friedman test. Those with p values<0.001 were further
evaluated by the Wilcoxon signed-rank test. Other statisti-
cal tests used were the t test for unequal variances and the
chi-square test. All p values were corrected for multiple
testing by multiplying the values with 20 (Bonferroni factor
for these data sets). Values were considered significant if
the corrected p values were ≤0.05. One evaluation datum
was missing and was carried forward from the previous
week. Because 8 of the 12 Tripterygium patients were on
1068 Clin Rheumatol (2010) 29:1067–1072DMARD, no analysis was carried out to compare effect of
Tripterygium on patients on DMARD to those not on
DMARD.
Results
The demographics and clinical characteristics of the 12
patients were listed in Table 1. The mean age was 36.2±
10.9 years, mean duration of disease 6.8±4.3 years, and
mean BASDAI value 52±11.4 (0–100 scale). While all
patients complained of spinal pain, swollen joints were
detected in only three. HLA-B27 was tested in ten patients
and was positive in nine. All patients were carefully
followed up for 6 weeks, except patient #6 who did not
return for the 6th week apparently because of lack of
response. Patient numbering was consecutive except #5
which did not exist.
By week 3 of treatment, the percent of patients showing
ASAS20 and ASAS40 response were 91.7% and 33.3%,
respectively. These appeared to be sustained to week 6
(Fig. 1). Statistically significant improvement as assessed
first by Friedman test (p<0.001), followed by Wilcoxon
signed-rank test, followed by correction for multiple testing
was observed with BAS-G, BASDAI, and BASFI starting
a tw e e k1( F i g .2). For BAS-G and BASDAI, the
improvement at week 6 exceeded those at week 3.
Statistically significant improvement for physician assess-
ment was observed at weeks 3 and 6. Although there was
improvement in BASMI, it was not statistically significant
after correction for multiple testing. At week 6, the ESR
decreased from 26.8±16.7 at week 0 to 9.8±5.8 (p=0.007
before Bonferroni correction). The decrease in CRP became
statistically significant at week 6 (p=0.04 after Bonferroni
correction; Fig. 2).
There were no clinically significant changes in CBC and
liver function tests. None of the patients reported of any
side effects such as headache or abdominal discomfort.
In a separate study, a total of 26 patients were given
placebo in a randomized double-blind controlled study
for etanercept. In this placebo group, NSAID, DMARD,
and corticosteroids were also maintained at the same
doses as in the baseline. The mean age of these patients
was 30.1±7.7 years, and the mean duration of disease
was 9.7±6.1 years. Out of 26 patients, 25 were male.
The mean BASDAI, BASFI, and BAS-G values are
s h o w ni nT a b l e2. At the entry of study, there were no
statistically significant differences between this placebo
group and the Tripterygium g r o u pi na g e ,d u r a t i o no f
disease, BASDAI, and BASFI. In the placebo group, after
6 weeks, even on placebo, there were 10–20% decrease in
the values of BASDAI, BASFI, and BAS-G. These
decreases were statistically significant in BASDAI and
BAS-G (p=0.0001 and 0.01), but not BASFI (p=0.09;
Table 2). The decreases in values of BASDAI, BASFI, and
BAS-G at week 6 of the Tripterygium group were about
60%, and compared to the corresponding values of the
placebo group, they were significantly lower in the
Tripterygium group (p=0.0001 for all three parameters;
Table 2 and Fig. 1). At week 6, the percent of patients in
the placebo group who achieved ASAS20 and ASAS40
were 30.8% and 3.8%, respectively. These were signifi-
cantly less than the corresponding values in the Triptery-
gium group (p<0.01 and <0.001, respectively).
Discussion
Extracts of T. wilfordii are being distributed in tablet form
as patent medicines by at least six pharmaceutical compa-
nies in China. The cost is about US $0.50 per day, which is
much lower than that of the biologics. They are widely used
by physicians practicing traditional medicine and accepted
by patients in China as standard treatment for several
inflammatory and autoimmune diseases, especially RA,
AS, SLE, and nephritis. A large number of publications,
mostly in the Chinese language, have been reported [2–4,
6]. It is also being used for AS. A total of 175 AS patients
treated with T. wilfordii have been reported in Chinese
language papers [3]. None of them used internationally
standardized evaluation instruments. Nevertheless, the drug
was reported as being 90% effective. Since a major side
effect of this drug is antifertility in male and amenorrhea in
female, and because many AS patients are in the reproduc-
tive age, it is imperative to understand the risk/benefit ratio
more precisely before continuing such indiscriminate use
[18]. Although the Jiangsu Province Hospital of Traditional
Chinese Medicine has been using this drug routinely for AS
resistant to conventional therapies, this study is also the first
in this institute to use internationally standardized evalua-
tion instruments to describe 12 consecutive disease-active
AS patients. The particular commercial preparation used in
this study was one which has been used in this hospital for
the past 5 years. The compilations of results of these 12
patients do show significant improvement in BAS-G,
BASDAI, BASFI, and physician assessment. One needs
to be cautioned that all these are subjective parameters.
Since these are case reports, no placebo-controlled data
were collected. In a recent placebo-controlled study of
etanercept in AS, also carried out in China, data are
available from 26 patients who received 6 weeks treatment
with placebo. At week 6, only 31% of those placebo-treated
patients showed an ASAS20 response. The results from
three separate published placebo-controlled study for TNFα
carried out in Caucasian countries also showed that the
ASAS20 response for placebo at weeks 4–8 are about 20%
Clin Rheumatol (2010) 29:1067–1072 1069Designation Age Gender Years of AS DMARD
Patient 1 31 F 2 Methotrexate (MTX)
Patient 2 42 M 13 Sulfasalazine
Patient 3 30 M 6 MTX + sulfasalzine
Patient 4 28 M 8
Patient 6 57 M 15
Patient 7 31 M 3
Patient 8 30 M 3 MTX + sulfasalzine
Patient 9 30 M 5 MTX
Patient 10 27 M 10 MTX
Patient 11 34 F 1.1
Patient 12 35 F 8 Sulfasalazine
Patient 13 59 M 7 Sulfasalazine + thalidomide
Mean 36.2 6.8
SD 10.9 4.3
Median 31.0 6.5
Designation BASDAI BASFI BASG Physician assessment Spinal pain
Patient 1 49.5 43 50 54 62
Patient 2 45.4 30.8 45 50 48
Patient 3 49.07 30.4 46 50 72
Patient 4 44.75 42.5 57 60 45
Patient 6 44.65 42.7 45 50 58
Patient 7 54.4 41.2 50 54 65
Patient 8 70 45.1 45 50 65
Patient 9 45.8 53.9 72 60 64
Patient 10 80.4 59.3 85 82 82
Patient 11 46.25 34.5 35 35 0
Patient 12 48.5 31.9 31 30 75
Patient 13 44.9 59.5 72 70 70
Mean 52.0 42.9 52.8 53.8 58.83
SD 11.4 10.3 16.0 13.9 21.28
Median 47.4 42.6 48.0 52.0 64.5
Designation ESR CRP Swollen joints Tragus to wall distance Schober test
Patient 1 15 4.2 0 20 3
Patient 2 46 13.09 0 17 2
Patient 3 16 6.02 0 17 2.5
Patient 4 58 26.6 0 15 2.5
Patient 6 10 1 0 14 2.5
Patient 7 8 6.33 1 10 4
Patient 8 43 10 0 10 2.5
Patient 9 10 8.7 2 18 1
Patient 10 14 11.2 1 15 1
Patient 11 33 5.1 6 10 4.5
Patient 12 34 6.07 0 12 3.5
Patient 13 34 6.07 0 10 2
Mean 26.8 8.7 0.83 14.00 2.58
SD 16.7 6.5 1.75 3.57 1.06
Median 24.5 6.2 0 14.5 2.5
Table 1 Demographics and
patient characteristics at entry
There is no patient #5. Units of
measurements are in text.
MTX was at 10 mg week
-1,
sulfasalazine at 1.5 gday
-1, and
thalidomide at 100 mg day
-1.
1070 Clin Rheumatol (2010) 29:1067–1072[19–21]. Hence, the observation that about 90% of patients
on Tripterygium achieved ASAS20 at week 6 is very
encouraging. Because such comparisons across studies
provide very little degree of confidence, we also attempted
to document the response to Tripterygium more objectively
using the acute phase reactants. There appears to be
statistically significant improvement in the serum CRP,
with some suppression also in ESR, although not to a
statistically less significant degree.
Each of our patients was also questioned for possible
drug-related side effects. Surprisingly, none of the patients
complained of side effect, perhaps because this drug is
widely accepted by patients as a standard therapy in a
traditional medicine hospital. Also, perhaps because of the
short duration of the study, none of the three female patients
reported the expected amenorrhea. From numerous reports
in Chinese journals, the most serious side effect of
Tripterygium is that on fertility. In one study of 97 women
treated for dermatological diseases, hypomenorrhea was
observed in 39 patients, and amenorrhea in 9. There are less
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Fig. 2 Changes in parameters in
response to Tripterygium. Error
bars represent standard devia-
tions. The p values shown are in
comparison to corresponding
values at week 0. Where p
values are not shown, they are
more than 0.05. All p values
have been corrected for multiple
testing. Numbers inside squares
represent median values of the
corresponding points
Table 2 Changes in disease status in patients on placebo
Week 0 Week 6
BASDAI 57.3±11.2 44.7±17.4
BASFI 50.4±21.1 45.1±24.8
BAS-G 72.8±21.1 60.3±19.4
Scores are in scale 0–100
Changes in BASDAI and BAS-G were statistically significant
Clin Rheumatol (2010) 29:1067–1072 1071documentations of the effect of Tripterygium on male
fertility. In the same study on dermatological diseases,
abnormalities of sperm were detected in 24 of 66 male
patients. All these occur within 3–5 weeks after starting
Tripterygium [22]. There is no assurance that this adverse
effect on fertility is not permanent. In addition to adverse
effect for fertility, the frequency of liver toxicity has been
reported to be as high as 30% and marrow suppression to
be 15% [18]. We did not observe these side effects in any of
our 12 patients perhaps because of the brevity of the study.
Our results carry a high risk of observer and patient bias.
The high degree of response might reflect such errors in a
culture where Tripterygium has been accepted as standard
therapy. Based on the reports on toxicity, Tripterygium
should not be initiated for any diseases by physicians with
no experience with this medication. AS patients should
regard the usefulness of Tripterygium with skepticism. For
it to be continued to be used in AS in any country, a
placebo-controlled study should be carried out to evaluate
the risk/benefit ratio. At the minimum, our results can
provide some basis for power analysis for such future
studies.
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